More on IDYA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $36.12 |
|
|||
| Open | $36.35 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $36.35 | ||||
| Day Low | $34.54 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,128,966 | ||||
- IDEAYA's IDE849 shows early survival data in relapsed lung cancer
- IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroend
- IDEAYA shares uveal melanoma trial data from three studies at ESMO
- IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Jou
- Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens - Ph2 OptiMUM-01 Results Coming Up
- William Blair Starts Ideaya Biosciences (IDYA) at Outperform
- Stifel Starts Ideaya Biosciences (IDYA) at Buy
- Form 4 IDEAYA Biosciences, Inc. For: Oct 06 Filed by: Hata Yujiro S
- Form 144 IDEAYA Biosciences, Inc. Filed by: Hata Yujiro S
- Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
Entities mentioned with IDYA
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- JPMorgan | View Related Stories »
- Jefferies & Co | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Show More...
